Sign in
CompletedNo phase

Oral Corticosteroids' Role in Pediatric Obstructive Sleep Apnea

Key facts

Who runs it
Hotel Dieu de France Hospital
Where
Lebanon1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
87 people enrolled
Started
9 Dec 2022
Ended
15 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Adenotonsillectomy
  • Prednisolone
Record updated
17 April 2025

Who can take part

Age
18 months to 8 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • All children aged between 18 months and 8 years diagnosed with OSAS secondary to adenotonsillar hypertrophy

Who cannot take part

  • History of acute or chronic cardiorespiratory neuromuscular, or metabolic diseases
  • Chromosomal disorders
  • Epilepsy
  • Children under 18 months or over 8 years old
  • Congenital craniofacial anomalies

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective interventional clinical trial (non-randomized) aims to evaluate oral corticosteroids' role as an alternative to surgery (gold-standard) in the treatment of obstructive sleep apnea in children. It also evaluates the evolution of symptoms' severity as well as any side effects linked to treatment.

Read full original descriptionShow less

This prospective study included children aged between 18 months and 8 years who consulted the same pediatric ENT physician's clinic for OSA secondary to adenotonsillar hypertrophy with no other comorbidities. They were divided into 2 Groups. Children undergoing intracapsular adenotonsillectomy by Coblation™ (Group 1) were compared to those receiving oral prednisolone at a dose of 1mg/kg for 5 days and 1 month of intranasal corticosteroids (Group 2). The follow-up tools were the Pediatric Sleep Questionnaire (PSQ) score and the size of the tonsils (Brodsky classification) evaluated at 1, 3 and 6 months.

The 2 groups in the trial

  • Patients undergoing surgical treatment (adenotonsillectomy).Existing treatment, for comparison

    Children undergoing adenoidectomy and intracapsular tonsillectomy using Coblation™, by the same surgeon at HDF.

    Treatment: Adenotonsillectomy

  • Patients undergoing medical treatment (short-term and low dose oral corticosteroids).Treatment being tested

    The second Group includes children whose parents have refused surgery despite informed understanding of the therapeutic algorithm of OSA. They received medical treatment consisting of a 1-month treatment with intranasal corticosteroids, coupled with a 5-day course of oral corticosteroids (prednisolone) at a safe dose of 1mg/kg.

    Treatment: Prednisolone

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Oral Corticosteroids' Role in Pediatric Obstructive Sleep Apnea, a Non-Randomized Controlled Trial.
Record updated
17 April 2025